This article summarizes a study evaluating Electroacupuncture (EA) as a synergistic adjunct therapy for Non-Small-Cell Lung Cancer (NSCLC), particularly addressing complications arising from chemotherapy, such as resistance, bone marrow suppression, and immunosuppression. The research, conducted using an NSCLC mouse model, combined EA applied at Zusanli (ST 36) and Sanyinjiao (SP 6) with the chemotherapy drug cisplatin. The findings were robust: EA combined with low-dose cisplatin significantly reduced tumor volume by 76%, marking superior tumor suppression compared to cisplatin alone (45% reduction). Mechanistically, EA enhanced the anti-tumor immune response by upregulating immune-related genes and increasing the infiltration of anti-tumor immune cells, including CD8+ T cells and M1 macrophages. Critically, EA provided substantial protection against chemotherapy-induced toxicity by safeguarding bone marrow hematopoiesis, enhancing progenitor cell function, and increasing peripheral leukocytes. The study identified the PACAP-PAC1 pathway as a potential underlying mechanism for EA’s immunomodulatory and hematopoietic benefits. These results strongly suggest that EA, utilized at ST 36 and SP 6, serves as a safe and highly practical adjuvant in the clinical management of NSCLC, enhancing treatment response while minimizing debilitating toxicity.